Wockhardt settles ongoing commercial litigation with Teva

23 Jun 2017 Evaluate

Wockhardt and its two subsidiaries, Wockhardt UK Holdings and CP Pharmaceuticals (CP), in the United Kingdom (collectively Wockhardt) have settled an ongoing commercial litigation before the High Court in London, United Kingdom in relation to a supply contract for a drug named Trisenox.

The dispute between the parties was in respect of the price charged by CP to its counterparty to the contract, Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva). The proceedings commenced in September 2015.

Under the terms of settlement, CP has agreed to waive its claim for the outstanding trade receivable of GBP 20 million and accordingly dropped its counterclaim for the said amount and further paid a sum of GBP 23 million to Teva and Cephalon by way of full and final settlement of Teva’s claims.

The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed and all claims are dismissed.


Wockhardt Share Price

1467.25 -51.35 (-3.38%)
06-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1846.95
Dr. Reddys Lab 1350.65
Cipla 1490.55
Lupin 2357.75
Zydus Lifesciences 961.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.